Commentary

Video

Dissecting Immunotherapy Options for TNBC

Author(s):

Margaret E. Gatti-Mays, MD, MPH, FACP

Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.

Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.

Related Videos
Sunil Adige, MD
Seth Wander, MD, PhD
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Cynthia X. Ma, MD, PhD
Ann H. Partridge, MD, MPH
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Virginia Kaklamani, MD
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Related Content
Nancy Lin, MD
October 16th 2024

T-DXd Demonstrates Efficacy in HER2+ Metastatic Breast Cancer With Stable or Active Brain Metastases

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

David Weintritt, MD, FACS
October 14th 2024

Empowering Breast Surgeons: A Call for Collective Action

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.
October 12th 2024

The OncFive: Top Oncology Articles for the Week of 10/6

FDA
October 11th 2024

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer